Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups
EP Europace · 30.03.2023 · 25 (3) · 1041-1050
DOI: 10.1093/europace/euad016 ↗Kurz gefasst
Klinische Studie in der Zeitschrift EP Europace, online erschienen am 09.02.2023. Verfasst von Serge Boveda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinique Pasteur, 45 Avenue de Lombez BP 27617, 31076 Toulouse Cedex 3, France. Hauptthemen laut MEDLINE: Heart Valve Diseases, Kidney Failure, Chronic, Pacemaker, Artificial. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Medtronic Inc.
Abstract (Originalsprache)
Aims
This study compares clinical outcomes between leadless pacemakers (leadless-VVI) and transvenous ventricular pacemakers (transvenous ventricular permanent-VVI) in subgroups of patients at higher risk of pacemaker complications. Methods and results This study is based on the Micra Coverage with Evidence Development (CED) study. Patients from the Micra CED study were considered in a high-risk subgroup if they had a diagnosis of chronic kidney disease Stages 4–5 (CKD45), end-stage renal disease, malignancy, diabetes, tricuspid valve disease (TVD), or chronic obstructive pulmonary disease (COPD) 12 months prior to pacemaker implant. A pre-specified set of complications and reinterventions were identified using diagnosis and procedure codes. Competing risks models were used to compare reinterventions and complications between leadless-VVI and transvenous-VVI patients within each subgroup; results were adjusted for multiple comparisons. A post hoc comparison of a composite outcome of reinterventions and device complications was conducted. Out of 27 991 patients, 9858 leadless-VVI and 12 157 transvenous-VVI patients have at least one high-risk comorbidity. Compared to transvenous-VVI patients, leadless-VVI patients in four subgroups [malignancy, HR 0.68 (0.48–0.95); diabetes, HR 0.69 (0.53–0.89); TVD, HR 0.60 (0.44–0.82); COPD, HR 0.73 (0.55–0.98)] had fewer complications, in three subgroups [diabetes, HR 0.58 (0.37–0.89); TVD, HR 0.46 (0.28–0.76); COPD, HR 0.51 (0.29–0.90)) had fewer reinterventions, and in four subgroups (malignancy, HR 0.52 (0.32–0.83); diabetes, HR 0.52 (0.35–0.77); TVD, HR 0.44 (0.28–0.70); COPD, HR 0.55 (0.34–0.89)] had lower rates of the combined outcome.
Conclusion
In a real-world study, leadless pacemaker patients had lower 2-year complications and reinterventions rates compared with transvenous-VVI pacing in several high-risk subgroups. Trial Registration ClinicalTrials.gov ID NCT03039712
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinique Pasteur, 45 Avenue de Lombez BP 27617, 31076 Toulouse Cedex 3, France.
- Medtronic, Inc., Minneapolis, MN, USA.
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
- Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Serge Boveda, Lucas Higuera, Colleen Longacre, Claudia Wolff, Kael Wherry, Kurt Stromberg
Förderung
- Medtronic Inc
Zitieren
APA
Boveda, S., Higuera, L., Longacre, C., Wolff, C., Wherry, K., Stromberg, K., & El-Chami, M. F. (2023). Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups. EP Europace, 25(3), 1041-1050. https://doi.org/10.1093/europace/euad016
Vancouver
Boveda S, Higuera L, Longacre C, Wolff C, Wherry K, Stromberg K, et al. Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups. EP Europace. 2023;25(3):1041-1050. doi:10.1093/europace/euad016
BibTeX
@article{Boveda2023,
author = {Boveda, Serge and Higuera, Lucas and Longacre, Colleen and Wolff, Claudia and Wherry, Kael and Stromberg, Kurt and El-Chami, Mikhael F},
title = {Two-year outcomes of leadless vs. transvenous single-chamber ventricular pacemaker in high-risk subgroups},
journal = {EP Europace},
year = {2023},
volume = {25},
number = {3},
pages = {1041--1050},
doi = {10.1093/europace/euad016}
}
EUVIMED